Concurrent incidence of esophageal squamous cell carcinoma and gastric adenocarcinoma: a report of three cases

The purpose of the study was to investigate rare cases of concurrent incidence of esophageal squamous cell carcinoma and gastric adenocarcinoma to develop an effective treatment strategy.

Material and Methods. Herein, we present a report of three cases of simultaneous occurrence of esophageal squamous cell carcinoma and gastric adenocarcinoma treated at the Regional Clinical Oncology Center in Ulyanovsk and Sverdlovsk Regional Oncology Center in Yekaterinburg. The patients underwent surgery, chemotherapy and radiation therapy.

Results. Synchronous esophageal squamous cell carcinoma and gastric adenocarcinoma pose significant treatment challenges, necessitating a multidisciplinary team of specialists. Chemoradiotherapy with the FOLFOX regimen demonstrated favorable tolerability and satisfactory clinical response.

Conclusion. A multimodal approach, involving surgery and chemoradiotherapy with the FOLFOX scheme, may be a valuable option for the treatment of patients with synchronous esophageal squamous cell carcinoma and gastric adenocarcinoma.

1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229–63. doi: 10.3322/caac.21834.

2. Zhan X., He L., Song K., Cao S., Meng E., Wang Y. Case Report: Triple Primary Malignant Tumors of the Esophagus, Stomach, and Colon in a Patient With Genetic Analysis. Front Genet. 2021; 12: 676497. doi: 10.3389/fgene.2021.676497.

3. Cui Y., Ren W., Du X., Yang L., Tan B. Research Progress of Multiple Primary Malignancies Associated With Esophageal Cancer. Cancer Control. 2023; 30: 10732748231176641. doi: 10.1177/10732748231176641.

4. Pisareva L.F., Odintsova I.N., Ananina O.A., Afanasyev S.G., Volkov M.Yu., Davydov I.M. Gastric cancer in Tomsk region: epidemiological aspects. Siberian Journal of Oncology. 2013; (3): 40–42. (in Russian). EDN: RQACBD.

5. Hirao M., Katada C., Yokoyama T., Yano T., Suzuki H., Furue Y., Yamamoto K., Doyama H., Koike T., Tamaoki M., Kawata N., Kawahara Y., Katagiri A., Ogata T., Yamanouchi T., Kiyokawa H., Kawakubo H., Konno M., Ishikawa H., Yokoyama A., Muto M. Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma. Gastric Cancer. 2023; 26(6): 988–1001. doi: 10.1007/s10120-023-01413-1.

6. Lim S.K., Sampson C.C., Warner O.G. Simultaneous primary carcinomas--a report of three cases. J Natl Med Assoc. 1981; 73(5): 413–17.

7. Toneev E.A., Pikin O.V., Martynov A.A., Firstov A.A. Surgical and multimodality treatment of patients with cancer of the thoracic esophagus in the regional oncology center. Russian Journal of Thoracic and Cardiovascular Surgery. 2023; 65(5): 579–88. (in Russian). doi: 10.24022/0236-2791-2023-65-5579-588. EDN: IAWKZU.

8. Ryabov A.B., Khomyakov V.M., Sobolev D.D., Kolobaev I.V., Chayka A.V., Vashakmadze L.A., Mamontov A.S., Pikin O.V. Immediate results of surgical and combined treatment in patients with thoracic esophageal cancer. P.A. Herzen Journal of Oncology. 2021; 10(6): 19–28. (in Russian). doi: 10.17116/onkolog20211006118. EDN: OFMRDR.

9. Li X., Lin S., Zhang Y., Wang H. Synchronous primary esophageal squamous cell carcinoma and gastric adenocarcinoma: analysis of 41 cases treated in a single institution. Sci Rep. 2015; 5: 13335. doi: 10.1038/srep13335.

10. Vogt A., Schmid S., Heinimann K., Frick H., Herrmann C., Cerny T., Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017; 2(2): e000172. doi: 10.1136/esmoopen-2017000172.

11. Toneev Е.А., Pikin О.V., Dengina N.V., Ryabov А.B., Мartynov А.А., Galchin А.V., Isaev D.N., Firstov А.А., Prohorov D.D. Results of combined and chemoradiation treatment of patients with thoracic esophageal cancer according to the data of the regional cancer center. Siberian Journal of Oncology. 2023; 22(5): 84–95. (in Russian). doi: 10.21294/1814-4861-2023-22-5-84-95. EDN: CZVAAV.

12. Luo Z.H., Qi W.L., Jin A.F., Liao F.X., Liu Q., Zeng Q.Y. The role of 18F-FDG PET/CT in patients with synchronous multiple primary malignant neoplasms occurring at the same time. Front Oncol. 2022; 12: 1068055. doi: 10.3389/fonc.2022.1068055.

13. Toneev E.A., Dengina N.V., Shagdaleev R.F., Prokhorov D.D., Martynov A.A., Anokhina E.P. The experience of using chemoradiotherapy for esophageal cancer with the FOLFOX chemotherapy regimen. Medical Advice. 2024; 18(21): 62–69. (in Russian). doi: 10.21518/ms2024-527. EDN: CMVUJR.

14. Kadono T., Yamamoto S., Hirose T., Ikeda G., Ohara A., Itoyama M., Yokoyama K., Honma Y., Hashimoto T., Sekine S., Ishiyama K., Oguma J., Daiko H., Kato K. Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus. 2023; 20(1): 109–15. doi: 10.1007/s10388-022-00951-4.

15. Conroy T., Galais M.P., Raoul J.L., Bouché O., Gourgou-Bourgade S., Douillard J.Y., Etienne P.L., Boige V., Martel-Lafay I., Michel P., LlacerMoscardo C., François E., Créhange G., Abdelghani M.B., Juzyna B., Bedenne L., Adenis A.; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014; 15(3): 305–14. doi: 10.1016/S1470-2045(14)70028-2. Erratum in: Lancet Oncol. 2014; 15(13): e587. Erratum in: Lancet Oncol. 2014; 15(13): e587. doi: 10.1016/S1470-2045(14)71151-9.

16. Toneev E.A., Dengina N.V., Anokhina E.P., Martynov A.A., Kulikov V.D., Galchin A.V., Starokon P.M., Blagovestnov D.A., Shabaev R.M., Choshiev A., Prokhorov D.D., Makarov P.M. Results of chemoradiotherapy with CROSS regimen for middle third esophageal cancer. Siberian Journal of Oncology. 2025; 24(3): 103–13. (in Russian). doi: 10.21294/1814-4861-2025-24-3103-113. EDN: VZWDFY.

17. Yoshii T., Hara H., Asayama M., Kumekawa Y., Miyazawa S., Takahashi N., Matsushima T., Shimizu S., Saito Y. Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. Mol Clin Oncol. 2020; 12(1): 23–30. doi: 10.3892/mco.2019.1945.

18. Ferreira R.P., Bussyguin D.S., Trombetta H., Melo V.J.D., Ximenez D.R., Preti V.B., Valladares G.C.G., Tomasich F.D.S., Abreu P. Treatment of esophageal cancer: surgical outcomes of 335 cases operated in a single center. Rev Col Bras Cir. 2021; 48: e20202723. doi: 10.1590/01006991e-20202723.

19. Jiang R., Wang Y., Xu J., Chen Z., Pang L. Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database. BMC Surg. 2023; 23(1): 175. doi: 10.1186/s12893-023-02072-w.